Replies to post #323858 on Avid Bioservices Inc (CDMO)

[horselover45]

I will second that.

[biopharm]

I agree and Immunoscore / Jerome Galon next at

Emerging Cellular Therapies: T Cells and Beyond (B6)
joint with the meeting on Lymphocytes and their Roles in Cancer (R1)

Scientific Organizers: Carl H. June, Marcela V. Maus and Bruce R. Blazar

February 11—15, 2018
Keystone Resort, Keystone, Colorado, USA

Sponsored by BioLegend, Inc., Editas Medicine, Gilead Sciences, Inc., Juno Therapeutics, Regeneron Pharmaceuticals, Inc., Sangamo Therapeutics, Inc. and Takeda Pharmaceutical Company Limited
...
...

....interesting that the Standstill Agreement has parties sending any updates to Peregrine now CDMO legal Mark Z....ALONG with Paul Hastings and M/A / licensesing..etc has had a big deal already announced it with MSK / Takeda etc and one has to first ask why Paul Hastings included in this Standstill Agreement ....and then out some puzzle pieces together as Biomarkers / ImmunoScore are on the verge of FDA acceptance

....but TILL that time, I guess Renegade Roger Lias expected us to believe in some residual value BS


Takeda Pharmaceutical Company, Bay City Capital and Deerfield Management Partner with Memorial Sloan Kettering Cancer Center, The Rockefeller University and Weill Cornell Medicine on Launch of Pioneering Drug Discovery Company Bridge Medicines
November 01, 2016
...
....
https://www.paulhastings.com/news/details/?id=5bc0ea69-2334-6428-811c-ff00004cbded